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Anovelcationicpolymer,dextran-spermine(D-SPM),hasbeenfoundtomediategeneexpressioninawidevarietyofcelllinesand
in vivo through systemic delivery. Here, we extended the observations by determining the optimal conditions for gene expression
of D-SPM/plasmid DNA (D-SPM/pDNA) in cell lines and in the lungs of BALB/c mice via instillation delivery. In vitro studies
showed that D-SPM could partially protect pDNA from degradation by nuclease and exhibited optimal gene transfer eﬃciency
at D-SPM to pDNA weight-mixing ratio of 12. In the lungs of mice, the levels of gene expression generated by D-SPM/pDNA
are highly dependent on the weight-mixing ratio of D-SPM to pDNA, amount of pDNA in the complex, and the assay time
postdelivery. Readministration of the complex at day 1 following the ﬁrst dosing showed no signiﬁcant eﬀect on the retention and
duration of gene expression. The study also showed that there was a clear trend of increasing size of the complexes as the amount
of pDNA was increased, where the sizes of the D-SPM/pDNA complexes were within the nanometer range.
1.Introduction
The success of gene therapy has largely depended upon
the development of delivery vectors, which are able to
eﬃciently and selectively deliver genes to target cells. Viral
vectors are able to mediate gene transfer with high eﬃ-
ciency with the possibility of long-term gene expression.
However, their broad use is aﬀected by the limited size
of the genetic material that can be delivered and the
possibility of insertional mutagenesis [1]. In light of these
concerns, nonviral gene delivery has emerged as a promising
alternative. Among the variety of diﬀerent materials which
have been utilized in the production of nonviral vectors
[2–5], polycations are considered to be a potent candidate
due to their ease of preparation, puriﬁcation, stability, and
the capacity to modify their physicochemical properties
[6, 7]. Over the years, a signiﬁcant number of cationic
polymers in linear or branched conﬁguration have been2 Journal of Biomedicine and Biotechnology
explored as carriers for gene delivery. These include poly-
L-lysine [8], polyethylenimine (PEI) [9, 10], dendrimers
(polyamidoamineandpolypropylamine)[6,7],chitosan[11,
12], cationic proteins (histones, protamine, and polylysine)
[13, 14], and diethylaminoethyl dextran (DEAE-dextran)
[15]. Polycations facilitate the tight compaction of plasmid
DNA (pDNA) into small and positively charged complexes,
which are readily internalized via nonspeciﬁc adsorptive
endocytosis by a large variety of cells [16]. Polymers such as
PEI have a highly cationic-charged organic macromolecule,
which contains amino nitrogen as every third atom. Due
to its relatively high gene delivery eﬃciency [2, 17, 18]
and ready availability, branched 25-kDa PEI has become
a benchmark which other polymers are often compared
with. However, the long-term biocompatibility of amine-
containing polymers remains an important issue for use in
therapeutic application in vivo, as these polymers are not
readily biodegradable [19].
We have previously reported on the use of nonviral
gene vectors to enhance in vitro and in vivo gene transfec-
tion [20–24]. During recent years, we have been working
to synthesize a new class of biodegradable polycations
capable of complexing and transfecting various genes to
diﬀerent cell lines in relatively high yields. More than 300
diﬀerent polycations were prepared starting from various
natural polysaccharides and oligoamines having two to
four amino groups. These cationic polysaccharides were
prepared by reductive amination of the oligoamine and
periodate-oxidized polysaccharides. Although most of these
cationic conjugates formed stable complexes with pDNAs
as determined by ethidium bromide quenching assay, only
the dextran-spermine- (D-SPM- ) based polycations were
found to be highly eﬀective in transfecting various cell lines
[25–31]. Dextran-spermine conjugates have also been mod-
iﬁed with increasing amounts of polyethylene glycol chains
(PEG). While non-PEGylated dextran-spermine/pDNA (D-
SPM/pDNA) complexes only showed reporter gene expres-
sion locally in the muscle via intramuscular delivery, their
partially-PEGylated form exhibited systemic biodistribution,
followed by high levels of transgene expression in organs
remote from the site of injection (lungs, liver, kidney, spleen,
heart, and GI tract) [28] after intravenous delivery. This
phenomenon was probably attributed to the “shielding”
of the polycation complexes that reduced their surface
charge and minimized the plasma protein and erythrocyte
aggregation [32]; therefore prolonging the circulation of the
PEGylated complexes in the blood [33].
Even though intravenous delivery elicits high level of
geneexpressioninvariousorgans,topicaldeliverytothenose
viadirectinstillationoraerosolizationhasgreateradvantages
for the use in gene therapy for lung diseases as the gene
transfer is targeted exclusively to the lung; thus the gene is
deliveredneartotheareaofpathologyaspossible.Astudyby
Griesenbach et al. [34] has shown that intravenous adminis-
tration of liposome-DNA complexes led to deposition in the
alveolar region of the lung while intratracheal delivery led to
transfection at the epithelial cells lining of the bronchioles.
In addition, topical delivery via intranasal route enables the
gene to be localized in the lungs, which allows for lower dose
for treatment [35]. As it is a noninvasive route of delivery,
this can possibly reduce any deposition in the other organs.
Although multiple techniques for gene delivery to the lung
via intranasal delivery have been developed, including the
use of adenoviruses, adeno-associated viruses, lipoplex, and
polyethyleneimine,allhavedrawbacks,includingineﬃciency
of gene transfer, immunological responses, inﬂammation,
nonspeciﬁcity of cell targeting, and low levels of gene
expression [36, 37].
To date, no study has been performed to determine the
eﬃcacy of D-SPM polycation exclusively in the lung, via
intranasal delivery. In this study, we determined the optimal
conditions for gene expression in cell culture and in mouse
lungs via instillation delivery of D-SPM/pDNA complexes.
In addition, we also evaluated the size of the D-SPM/pDNA
particle complex and its pDNA protection eﬃciency against
an u c l e a s e .
2.MaterialsandMethods
2.1. Preparation of Plasmid DNA. Plasmid pCIKLux express-
ing luciferase reporter gene was kindly provided by the Gene
Medicine Research Group, Oxford University, UK and has
been described by Gill et al. [38]. Plasmid phMGFP carrying
greenﬂuorescentprotein(GFP)reportergenewaspurchased
from Promega (Madison, WI, USA). Both plasmids are
under the control of CMV immediate early gene promoter
and enhancer. The plasmids were replicated in the high-
copy AG 1 competent cells (Stratagene, La Jolla, CA, USA),
extracted and puriﬁed by EndoFree Plasmid Puriﬁcation
(Qiagen, Hilden, Germany). The puriﬁed plasmids were
veriﬁed based on their size and pattern by restriction enzyme
analysis in 1% agarose gel electrophoresis.
2.2. Preparation of D-SPM/pDNA Complex. For the cell
culture study, dextran-spermine (D-SPM) and pDNA com-
plexes were prepared at various D-SPM/pDNA weight-
m i x i n gr a t i o so f8t o1 8( μg dextran-spermine/μg pDNA)
(w/w). The complexes were vortexed brieﬂy and incubated
at room temperature for 30min. prior to being used.
Dextran-spermine solutions were added to 0.5μg pDNA
solution, each accounting for the increasing N/P weight
ratio, to Eppendorf tube containing Opti-MEM (Invitrogen,
Carlsbad, CA, USA) to obtain a ﬁnal volume of 200μLf o r
each well.
For the in vivo study, D-SPM/pDNA complexes at
weight-mixing ratios ranging from 14 to 18 were prepared,
with the concentration of DNA kept to 10μg. Once the
optimal weight-mixing ratio was identiﬁed, various con-
centrations of pDNA were employed to yield a ﬁxed D-
SPM/pDNAratio.TheD-SPM/pDNAcomplexwasprepared
to a ﬁnal volume of 100μL for dosing throughout the study.
The resulting solution was vortexed brieﬂy and allowed to
stand at room temperature for 30min. prior to use to allow
spontaneous complex formation.
2.3.ParticleSizeAnalysis. FreshD-SPM/pCIKLuxcomplexes
prepared to a ﬁxed weight-mixing ratio with a varyingJournal of Biomedicine and Biotechnology 3
concentration of pDNA were analyzed for mean particle
size by using a particle size analyzer (Nanophox, Sympatec,
Germany). The principle applied in this analyzer is the Pho-
ton Cross Correlation sensor allowing for the simultaneous
measurement of particle size and stability in the range of
approximately 1nm to several μm in opaque suspensions
and emulsions. D-SPM/pCIKLux complexes were prepared
by using the same amount of D-SPM with varying amount
of pDNAs. All the samples were dispersed in nuclease-free
water, and size determinations were performed at 25◦Ci n
triplicates in unweighted analysis.
2.4. DNase I Protection Assay. D-SPM/pDNA complexes at
ratios that showed optimal gene expression in cell culture
were incubated with 2 units of DNase I (Promega, Madison,
WI, USA) at 37◦C for 15 minutes in a ﬁnal volume of 10μL.
The digestion was halted by the addition of stop solution.
The integrity of pDNA released from the complexes was
assessed by 0.8% agarose gel at 75V.
2.5. Cell Culture. In vitro assays were performed on African
green monkey kidney ﬁbroblast (COS-7) cell line, which was
obtained from American Type Culture Collection (ATCC)
(Manassas, VA, USA). The COS-7 cell lines were cultured
in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (Gibco BRL, Paisley, UK), 4.5g/L D-glucose,
1.0mM sodium pyruvate, and 1.5g/L sodium bicarbonate
(Sigma-Aldrich). The cells were kept at 37◦C in humidiﬁed
5% CO2 atmosphere. Subculturing was performed when the
cells reached near conﬂuency.
2.6. Transfection of Cells Grown In Vitro. COS-7 cells were
seeded at a seeding density of 5 × 104 cells/well on a 24-well
plate and grown in 1mL DMEM/FBS at 37◦C in humidiﬁed
5% CO2 atmosphere for 24h for adherence. At the time of
transfection,cellgrowthmediumwasaspirated,washedwith
PBS, and replaced with the transfection medium without
serum. After 4h of transfection, 1mL of new complete
growth medium was gently overlaid, and cells were further
incubated for 48h under similar conditions. Branched
25kDa PEI was used as positive control. Brieﬂy, PEI/pDNA
was prepared at 10:1 N:P ratio, and the total of 420μLo f
themixturecomplexesinOpti-MEM(Invitrogen)wasadded
to each well and incubated for 24h. The media were then
exchanged for fresh complete media and further incubated
for another 24h. After the incubation period, cells were
washed with PBS and lysed by using 1X reporter lysis buﬀer
(RLB) (Promega, Madison, WI, USA).
2.7. Animals. Mice were maintained under conventional
housing conditions. Mice were fed with standard chow
and water ad libitum and were allowed to acclimatize for
at least 7 days prior to procedures being performed. All
animal experiments were carried out in accordance with
the Guidelines for Animal Experiments of Universiti Putra
Malaysia.
2.8. Animal Dosing and Analysis of Reporter Gene Activity.
Female BALB/c mice (6–8 weeks old) were anesthetized by
isoﬂuorane (Nicholas Piramal (I), Ltd., UK) inhalation until
a balanced state of anesthesia was achieved. D-SPM/pDNA
complexes, naked pDNA, and dextran-spermine only solu-
tions (D-SPM) were administered to the lungs by nasal
instillation during inspiration [39]. Unless stated otherwise,
100μL of either formulation was delivered into each mouse,
and the animals were euthanized 2 days postadministration.
Following euthanasia by cervical dislocation, the tracheas
and the lungs were removed and stored at −80◦Ci n
Reporter Lysis Buﬀer (Promega). After thawing, tissues were
homogenized using Ultra-Turrax (IKA, Staufen, Germany)
and the lysates were then passed through a QIAshredder
column (Qiagen). The luciferase activity for both in vitro
and in vivo samples was measured using a luciferase assay kit
(Promega) on a GloMax 20/20 luminometer (Promega). The
relative light units (RLUs) were normalized against protein
concentrationin the cellextracts,whichwasquantiﬁed using
a Bio-Rad DC Protein Assay (Bio-Rad Laboratories, CA,
USA).
2.9. Statistical Analysis. Distribution-free, nonparametric
Mann-Whitney U test was applied to compare two unpaired
groups of variable whereas ANOVA parametric test was
applied to multiple group comparison. Data were presented
as value ± SEM and considered to be statistically signiﬁcant
if P-values were <.05. Analyses were performed using SPSS
for Windows, Version 15.0.
3. Results and Discussion
3.1. Determination of Optimal Weight-Mixing Ratio of D-
SPM/pDNA In Vitro. The facilitated transfer of gene into
various cell lines is highly dependent on the optimized
culture conditions such as oxygen and nutrients supplement
[40]. Thus, it is essential to evaluate the optimal weight-
mixing (w/w) ratio of D-SPM to pDNA, which varied from
polymer to polymer beforehand for eﬃcient transfection. As
the main concern for the in vitro study was also to verify the
ability of D-SPM to deliver the gene into cell, COS-7 cells
ware chosen for this experiment as this cell line has been
shown to be eﬀectively transfected by D-SPM previously in
[30]. In this study, the cells were transfected with 0.5μgo f
pCIKLux complexed in a serum-free media with diﬀerent
amounts of dextran-spermine. Gene transfection eﬃciency
was measured as a function of D-SPM/pDNA weight-mixing
ratio and expressed as relative light unit (RLU) normalized
to total cells protein.
As shown in Figure 1, reporter gene activity was negli-
gible at weight ratio of 8 and 10. However, D-SPM/pDNA
was able to promote transfection in weight-mixing ratios
ranging from 12 to 18, with maximum level of expression
measured at weight-mixing ratio of 12 and 14. At this range,
nearly 2.9 × 106 RLU/mg protein was obtained, which was
signiﬁcantly higher than the established polycation trans-
fection agent, PEI (1.4×106 ±3.2×105 RLU/mg protein).4 Journal of Biomedicine and Biotechnology
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Figure 1: Transfection eﬃciency of D-SPM/pCIKLux complex at
various weight-mixing ratios with 0.5μg pCIKLux in COS-7 cells.
PEI was used as the positive control. Luciferase expression was
measured as RLU/mg protein after 48h posttransfection in serum-
free condition. Luciferase expressions signiﬁcantly higher than PEI
are denoted by asterisks (∗)( P<. 05) while from untreated are
denoted by dagger (†)( P<. 05). Data are presented as mean ± S. E.
M of experiments conducted in triplicate.
Increasing the w/w ratio above 14 did not improve the
transfection eﬃciency.
To ascertain that the transfection ability of the dextran-
spermine polycation conjugates was not plasmid or reporter
gene-speciﬁc, we performed transfection with another plas-
mid, phMGFP, following similar protocols described above.
Ratio ranging from 12 to 16 was chosen for this study as
they exhibited relatively high gene expression previously.
Expression of the reporter gene was estimated using an
inverted ﬂuorescent microscope (Figure 2). GFP expression
was detectable in cells transfected with all ratios of D-
SPM/pDNA, but their transfection eﬃciencies seemed to
be lower when compared to PEI/pDNA. The transfection
eﬃciency was further conﬁrmed by determining percent-
age of GFP-positive cells under ﬂow cytometry (Figure 3).
This quantitative analysis revealed that 13.37%, 11.52%,
and 7.61% out of 10,000cells expressed GFP following
transfection by D-SPM/pDNA at ratio 12, 14, and 16,
respectively. These percentages of cells expressing GFP were
higherthantheuntreated(0.34%)andnakedpDNA(3.84%)
but lower than PEI/pDNA (15.26%). These results support
the ﬂuorescence microscope observation.
Interestingly, dextran-spermine when complexed with
luciferase expressing plasmid showed signiﬁcantly higher
gene expression when compared to PEI, but not with the
GFPexpressingplasmid.Thisdiscrepancycouldbeexplained
by the diﬀerent strength of electrostatic interaction between
the DNA helices of each plasmid and the grafted spermine,
which may play a signiﬁcant role in the eﬃciency of cell
transfection. Therefore, although D-SPM was able to deliver
diﬀerent pDNAs into the cells eﬀectively, the reporter gene
activity might rely on the nature of the plasmid construct.
3.2. Characterizations
3.2.1. Eﬀect of DNase Treatment on pDNA Encapsulated by D-
SPM. Ideally, a vector should be able to encapsulate pDNA
eﬃciently under harsh environment conditions to enable
Table 1: Particle size of D-SPM/pDNA as a function of the pDNA
amount loaded to D-SPM at ratio 16, determined by Nanophox
particle size analyzer.
Sample Dextran-spermine/pDNA complex at
diﬀerent amount of DNA (Ratio 16) Size (nm)
1 15μg 52.44
2 20μg 68.85
3 25μg 94.31
4 30μg 115.49
longer retention time to allow more uptake of the pDNA by
the cells. Eﬃcient encapsulation by the vector is vital as the
slow mobility of pDNA in cytoplasm has made it to become
an easy target for the Ca2+-sensitive cytoplasmic nucleases
nucleases which may restrict the half-life of plasmid DNA
[41]. Therefore, to mimic the environment in the lungs
with the presence of nucleases, D-SPM/pCIKLux complexes
prepared at ratio 14, 16, and 18, containing 4μg pDNA,
were treated with DNase I to evaluate the protection level
conferred by D-SPM to the pDNA.
Gel electrophoresis results indicate that the D-SPM
at all ratios tested was able to form complexes with the
pDNA, shown by the immobility of DNA to move from
the well (lane 2, 4, and 6) (Figure 4). While free pDNA
was completely digested by the DNase (lane 9), D-SPM
encapsulated pDNA at all ratios was partially protected from
degradation (lane 3, 5, and 7). D-SPM/pDNA at ratio 16
conferred maximum protection to the pDNA from DNase
I degradation where brighter DNA was observed in the
well (lane 5) when compared to the DNase I treated D-
SPM/pDNA at other ratios. Taken together, this study shows
that the D-SPM/pDNA complexes could only minimally
protect the pDNA from the eﬀect of DNase I.
3.2.2. Eﬀect of Increasing the Amount of DNA on the Complex
Size. Prior to the in vivo study, it is important to know the
size of the complexes as smaller size gene carrier has been
shown to be capable of escaping the clearance eﬀect of the
reticuloendothelial system although it has longer retention
time in the system circulation [42–45]. Previous studies by
Kaul and Amiji [46] also noted the importance of small
size gene carrier in order to avoid the uptake by alveolar
macrophages.
The physical characteristic of D-SPM/pDNA by the size
measurement was carried out at a ﬁxed weight-mixing ratio
of D-SPM/pDNA complex at 16 by changing the pDNA
concentrations (15, 20, 25, and 30μg pDNA) only. At the
concentration of 15, 20, and 25μg of pDNA, the mean diam-
eterwasmeasuredat52.44,68.85,and93.41nm,respectively.
The complex loaded with 30μg pDNA resulted in the largest
complex size with a mean diameter of 115.49nm. The
study showed that there was a clear trend of increasing size
of the complexes as the amount of pDNA was increased
(Table 1). These results may be explained by the electrostatic
repulsions presence between the positively charged D-SPM
and the increasing amount of negatively charged pDNA,Journal of Biomedicine and Biotechnology 5
(a) (b) (c)
(d) (e) (f)
Figure 2: Fluorescent microscopy of GFP expression in COS-7 cell lines transfected with diﬀerent gene carriers. Fluorescent cells were
visualized at 48h post-transfection. (a) Untreated, (b) naked DNA, (c) PEI/phMGFP, (d) D-SPM/phMGFP at ratio 12, (e) D-SPM/phMGFP
at ratio 14, and (f) D-SPM/phMGFP at ratio16. (Magniﬁcation x10).
which caused the formation of less compact complexes [31].
The overall results indicate that the sizes of the complexes 6
prepared in this study were in a nanometer range. This was
in concordance with the observation by Hosseinkhani and
Tabata [47], where it was reported that the D-SPM/pDNA
prepared was in a nanometer size, although a larger bp size
of pDNA was used to prepare the complex compared to the
pDNA size used in this study. Considering that the amount
of pDNA inﬂuences the size of the complex, this analysis
provides a guideline for the determination of the range of
the pDNA amount to be used to obtain a maximal reporter
gene expression in mouse lungs in the following study.
3.3. Determination of Optimal Weight-Mixing Ratio and
Amount of pDNA of D-SPM/pDNA for Maximal Reporter
Gene Expression in Mouse Lungs. We further evaluated the
weight-mixing ratio of the D-SPM/pCIKLux complexes
that would give the most eﬃcient gene delivery in mouse
lung at day 2 postadministration. The BALB/c mice were
instilled intranasally with 10μg pCIKLux complexed with
diﬀerentamountofdextran-sperminetogiveD-SPM/pDNA
weight-mixing ratio ranging from 14 to 18. Intranasal
delivery of the naked pDNA and D-SPM controls exhibited
background reading of the na¨ ıve mice (44.34±4.51RLU/mg
lung protein) (Figure 5). Similar readings were observed
with D-SPM/pDNA complex at weight-mixing ratios of 14
and 15. The maximal reporter gene expression (91.23 ±
30.18RLU/mg lung protein) was observed at weight-mixing
ratio of 16 with almost 2-fold level of reporter gene expres-
sion in comparison to naked DNA. Unfortunately, the value
was not statistically signiﬁcant. No further improvement of
reporter gene activity was observed with the increase ratio of
the polycation.
To evaluate whether pDNA concentration inﬂuences the
maximal transfection eﬃciency of the D-SPM at weight-
mixing ratio of 16, mice were intranasally instilled with
D-SPM/pDNA complexes containing varying amount of
pCIKLux. The weight-mixing ratio of D-SPM/pDNA was
ﬁxed to 16, and the amount of pDNA administered was
varied from 9.5μg to 17.5μgp e rm o u s e .Figure 6 shows
the average luciferase activities in the mice lungs at 2 days
postadministration. At pCIKlux concentration of 9.5μga n d
11.5μg, the reporter gene expression levels were similar
to the background level exhibited by the untreated mice.
Maximum level of reporter gene expression was detected6 Journal of Biomedicine and Biotechnology
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Figure 3: Side scatter (SSC) versus GFP ﬂuorescent dot plot of transfected COS-7 cells showing positions of GFP-negative (R1) and GFP-
positive (R2) population with the percentage gated of GFP-positive cells using ﬂow cytometry analysis by using diﬀerent gene carriers. Gene
expression was measured at 48h post-transfection. (a) Untreated, (b) naked DNA, (c) PEI/phMGFP, (d) D-SPM/phMGFP at ratio 12, (e)
D-SPM/phMGFP at ratio 14, and (f) D-SPM/phMGFP at ratio16.
from mice administered with 13.5μg pCIKLux. At this
amount, the mean reporter gene activity was monitored
at 158.1 ± 79.6RLU/mg lung protein, approximately 3-fold
higher when compared to the untreated group. However,
increasing the amount of pCIKLux delivery beyond 13.5μg
did not show any improvement in the level of reporter
gene expression. It has been demonstrated that following
intramuscular injection of D-SPM/pDNA, the highest level
of gene expression was observed with 50μg pDNA delivered
per mouse [28]. Nevertheless, in our current study, we did
not see any improvement in the level of gene expression with
50μg of pDNA administered to the mouse via instillation
delivery (result not shown).
Even though the D-SPM/pDNA transfection conditions
which yield the maximum level of reporter gene expression
in the mouse lung have been identiﬁed, this value was
considered as a moderate increase from the level exhibited
by the untreated animals. There are several possible expla-
nations for this unexpectedly modest level of the luciferase
activity in vivo. As pointed out by Hosseinkhani et al. [28],Journal of Biomedicine and Biotechnology 7
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Figure 4: Agarose gel electrophoresis of D-SPM/pDNA complex
at diﬀerent ratios following DNase treatment. Lane 1: 1kb DNA
ladder; 2, 4, and 6: D-SPM complexes at ratio 14, 16, and 18,
respectively; 3, 5, and 7: D-SPM/pDNA complexes at ratio 14, 16,
and 18, respectively, treated with DNase I; 8: free pDNA; 9: free
pDNA treated with DNase I; 10: D-SPM only.
Naked
pDNA
D-SPM Untreated 14 15 16 18
0
20
40
60
80
100
120
140
Weight ratio (polymer/pDNA)
L
u
c
i
f
e
r
a
s
e
(
R
L
U
/
m
g
p
r
o
t
e
i
n
)
(
S
E
M
)
Figure 5: Luciferase expression (RLU/mg protein) in the trachea
and lung of BALB/c mice following administration of naked
pCIKLux, dextran-spermine only (D-SPM), and various weight-
mixing ratios of D-SPM/pCIKlux complexes ranging 14 to 18 at
2 days posttreatment. The amount of DNA was kept to 10μg.
Untreated mice was served as the control. Data are presented as
mean ± S.E.M from 6 animals.
there might be a likelihood of the D-SPM/pDNA complexes
to be removed by the reticuloendothelial system from the
capillaries in the lung, which resulted in the ineﬃciency of
speciﬁc targeting capability of the polycation to the lung
epithelial cells. Next is from the aspect of the interaction
between the complexes with the serum proteins such as
albumin, albeit low in the lung, might increase the tendency
of the DNA release and eventually reduced the interaction
between the intact DNA with target cells [31].
3.4. Reporter Gene Expression Time Point Proﬁle. For the
previous experiments, all the luciferase assays were done
at 2 days post-treatment, as suggested in the luciferase
assay protocol (Promega, USA). Evaluations of the luciferase
expression for D-SPM were also performed at 2 days post-
treatment by Hosseinkhani et al. [28], which exhibited
optimum transfection eﬃciency. However, in this study, the
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Figure 6: Luciferase expression (RLU/mg protein) in the trachea
and lung of BALB/c mice following the administration of D-SPM
complexed with diﬀerent amount of pCIKLux, at 2 days post-
treatment.Thew/wratiowaskeptat16.Untreatedmicewereserved
as the control. Data are presented as mean ± S.E.M from 6 animals.
target cells for gene delivery were diﬀerent, and therefore
after all the parameters including the weight-mixing ratios
and amount of pDNA of D-SPM/pDNA for maximal
reporter gene expression have been optimized, there was a
need to determine the time point when the level of gene
expression was at its peak.
Based on the study carried out by Wei et al. [48]w h i c h
reported that 6h duration was adequate for carrier/pDNA
complex to enter the cells in vitro, a minimum time of 6h
was selected to sacriﬁce the mice. Conversely, the maximum
time point of seven days was chosen as the level of reporter
gene expression by a nonviral vector would normally reach
negligible value by day 4 postinstillation [38] .T h u s ,at i m e
point proﬁle study over a period of seven days was carried
out in this study.
As the amount of pDNA of the D-SPM/pDNA complex
was 13.5μg showed the highest reporter gene expression,
subsequent experiments employed this amount of pDNA,
while the w/w ratio was kept to 16. The D-SPM/pDNA
complexes were administered to each mouse, and the
animals were sacriﬁced at several time points within a week.
At 6h postadministration, the level of luciferase activity
was negligible (Figure 7, ﬁlled squares). Maximum gene
expression was detected at day 1 with luciferase reading
at 274.6 ± 109.8RLU/mg lung protein, dropped markedly,
and eventually reached insigniﬁcant value by day 2. These
results show that airway gene expression mediated by D-
SPM/pDNA was transient. The transient phenomenon may
be attributed to the transcriptional inactivation of the
cytomegalovirus (CMV) promoter used in pCIKLux in this
study. It was reported that this strong viral promoter confers
high level of gene expression in vivo but does not direct
persistent transgene expression and undergoes promoter
attenuationinresponsetoinﬂammatory-mediatedcytokines
[49, 50]. Since the highest reporter gene expression level
was detected at day 1 postadministration, the following
experiments were performed using D-SPM/pDNA at w/w
ratio 16, with 13.5μg pDNA where the mice were sacriﬁced
at day 1 postadministration.8 Journal of Biomedicine and Biotechnology
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Figure 7: Luciferase expression (RLU/mg protein) in the trachea
and lung of BALB/c mice following the administration of D-
SPM/pDNA at ratio 16, containing 13.5μg pDNA with succeeding
readministration post 24h of ﬁrst dosing. The vertical arrow
pointing downward indicates the time point of readministration
after the initial administration. The horizontal dash line represents
the approximate sensitivity of the assay. Data are presented as mean
± S.E.M from 6 animals.
3.5.RepeatAdministrationofD-SPM/pDNAtotheMouseAir-
ways. One of the fundamental challenges in gene therapy is
thepersistenttransgeneexpression.However,D-SPM/pDNA
administration with plasmid controlled by CMV promoter
only resulted in a transient reporter gene expression. One
way to increase the duration as well as to maintain the
level of transgene expression is by repeating the adminis-
trations of the therapeutic gene. It has been proven that
repeat administrations of the therapeutic gene are critical
in treating chronic lung diseases, which require lifelong
treatment such as cystic ﬁbrosis, asthma, and emphysema
[51]. Hence, repeat administration of the D-SPM/pDNA
study was performed to evaluate if this procedure could have
ap o s i t i v ee ﬀect on the duration of reporter gene expression.
In this study, another dose of D-SPM/pDNA (at w/w
ratio of 16 and pDNA amount of 13.5μg) was administered
to the mice at day 1 postinitial administration. The level
of luciferase activities were measured at 6h, 1 day, 2 days,
and 4 days post readministration. The highest reporter gene
expression was detected at 6-hour post readministration
(174.1±81.6RLU/mglungprotein)butdroppedmarkedlyto
insigniﬁcant level by day 1 post readministration (Figure 7,
opencircles).Thisclearlyshowsthatrepeatedadministration
ofD-SPM/pDNAdidnotaugmenttheﬁrstadministrationto
enhance or even to restore the luciferase activity.
Readministration of D-SPM/pDNA might result in the
increased amount of the complexes, which could inad-
vertently interact with the serum protein in the lungs.
Accumulation of the aggregates of D-SPM/pDNA and serum
protein could entrap the pDNA inside the complex by
impeding the disassociation of the pDNA from the D-
SPM, after its uptake into the cells’ cytoplasm. The reduced
number of free pDNA in the nucleus of the targeted cell
is reﬂected by the decreased level of reporter gene activity
[52]. On another paper, the eﬀect of repeated anaesthesia on
mouse and the development of neutralizing antibody to the
luciferase protein could probably contribute to the reduced
luciferase activity of the second dosing [53]. It is expected
that the readministration of the D-SPM with pDNA carrying
reporter gene other than luciferase, following the initial
administration of D-SPM/pCIKLux, will show a better level
of gene expression due to the absence of existing neutralizing
antibody against the second reporter gene [28, 47].
Other investigators have also reported the ineﬃciency
of the repeated administrations by nonviral vectors in vivo.
Griesenbach and Alton [54] observed that the expression
of the transgene was reduced and eventually absent from
the cell even after more than 2 repeated administrations of
the gene delivery complex. Earlier observations by Wiseman
et al. [53] showed that repeated dosing of linear 22kDa
polyethylenimine PEI failed to provide higher reporter gene
activity as compared to the initial dose. Almost similar result
was obtained from the study done by Orson et al. [55],
which highlighted that repeated intravenous administration
of the same dose of protein/PEI/pDNA complexes encoding
luciferase reporter gene was unsuccessful in increasing the
luciferase activity.
4. Conclusion
This paper demonstrates that dextran-spermine (D-SPM)
gene delivery into the lung resulted in modest level of
reporter gene expression as compared to the control animals.
D-SPM/pDNA exhibited transient gene expression in the
mouse lung with no signiﬁcant improvement on the level
or persistency of gene expression following readministration
of the complex. We also showed that the D-SPM/pDNA
complexwasformedwithinananometerrange.Theinability
of the polymer to eﬃciently protect the DNA from degra-
dation by DNase I shown here probably translates to the
low transfection eﬃciency seen in the lungs as the complex
might not be able to shield the pDNA against the eﬀects
of the endogenous nucleases. Taken together, this study
suggests that further work needs to focus on increasing the
transfection eﬃciency of the D-SPM. This could be done
by modifying the physiochemical properties of the D-SPM,
such as the particle charge and aggregation tendency to
mimic the chemical properties of a highly eﬃcient nonviral
gene delivery agent available in the market. In addition, the
evaluationonthesafetyproﬁlesofD-SPMasagenecarrierto
the lung, which has not been performed in this study, should
be conducted to complement the reporter gene expression
results.
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